Page 68 - 《中国药房》2025年10期

persistence and adherence[J]. Patient Prefer Adherence， of a state-transition microsimulation cost-effectiveness
2016，10：415-423. model[J]. Osteoporos Int，2015，26（5）：1477-1489.
[ 5 ] GAO L，MOODIE M，WATTS J J，et al. Cost- [18] KLOTZBUECHER C M，ROSS P D，LANDSMAN P B，
effectiveness of osteoporosis opportunistic screening et al. Patients with prior fractures have an increased risk
using computed tomography in China[J]. Value Health of future fractures：a summary of the literature and statisti‐
Reg Issues，2023，38：38-44. cal synthesis[J]. J Bone Miner Res，2000，15（4）：721-739.
[ 6 ] YOU R X，ZHANG Y，WU D B，et al. Cost-effectiveness [19] CHANG C Y，TANG C H，CHEN K C，et al. The morta-
of zoledronic acid versus oral alendronate for postmeno‐ lity and direct medical costs of osteoporotic fractures
pausal osteoporotic women in China[J]. Front Pharmacol， among postmenopausal women in Taiwan [J]. Osteoporos
2020，11：456. Int，2016，27（2）：665-676.
[ 7 ] LI N，ZHENG B，LIU M B，et al. Cost-effectiveness of an‐ [20] QU B，MA Y，YAN M，et al. The economic burden of frac‐
tiosteoporosis strategies for postmenopausal women with ture patients with osteoporosis in western China[J]. Osteo‐
osteoporosis in China[J]. Menopause，2019，26（8）： poros Int，2014，25（7）：1853-1860.
906-914. [21] YANG Y C，DU F，YE W Y，et al. Inpatient cost of trea-
[ 8 ] HILIGSMANN M，REGINSTER J Y，TOSTESON A A， ting osteoporotic fractures in mainland China：a descrip‐
et al. Recommendations for the conduct of economic tive analysis[J]. Clinicoecon Outcomes Res，2015，7：
evaluations in osteoporosis：outcomes of an experts’ con‐ 205-212.
sensus meeting organized by the European Society for [22] YANG Z H，BUSSCHBACH J，LIU G，et al. EQ-5D-5L
Clinical and Economic Aspects of Osteoporosis，Osteoar‐ norms for the urban Chinese population in China[J].
thritis and Musculoskeletal Diseases（ESCEO）and the US Health Qual Life Outcomes，2018，16（1）：210.
branch of the International Osteoporosis Foundation[J]. [23] HILIGSMANN M，ETHGEN O，RICHY F，et al. Utility
Osteoporos Int，2019，30（1）：45-57. values associated with osteoporotic fracture：a systematic
[ 9 ] MORI T，CRANDALL C J，GANZ D A. Cost- review of the literature[J]. Calcif Tissue Int，2008，82（4）：
effectiveness of denosumab versus oral alendronate for eld- 288-292.
erly osteoporotic women in Japan[J]. Osteoporos Int， [24] ZHU Y B，XING X，LIU S，et al. Epidemiology of low-
2017，28（5）：1733-1744. energy wrist，hip，and spine fractures in Chinese popula‐
[10] JÖNSSON B，STRÖM O，EISMAN J A，et al. Cost- tions 50 years or older：a national population-based survey
effectiveness of denosumab for the treatment of postmeno‐ [J]. Medicine（Baltimore），2020，99（5）：e18531.
pausal osteoporosis[J]. Osteoporos Int，2011，22（3）： [25] MATSUMOTO T，ITO M，HAYASHI Y，et al. A new ac‐
967-982. tive vitamin D3 analog，eldecalcitol，prevents the risk of
[11] JIANG Y，TANG H，MA X L，et al. Eldecalcitol increases osteoporotic fractures：a randomized，active comparator，
bone mineral density in Chinese osteoporotic patients double-blind study[J]. Bone，2011，49（4）：605-612.
without vitamin D or calcium supplementation[J]. J Bone [26] SUN S，CHEN J Y，JOHANNESSON M，et al. Population
Miner Metab，2019，37（6）：1036-1047. health status in China：EQ-5D results，by age，sex and
[12] 刘国恩. 中国药物经济学评价指南2020[M]. 北京：中国 socio-economic status，from the national health services
市场出版社，2020：27. survey 2008[J]. Qual Life Res，2011，20（3）：309-320.
[13] HIGGINS J P T，THOMAS J，CHANDLER J，et al . Co‐ [27] GORAI I，TANAKA Y，HATTORI S，et al. Assessment of
chrane handbook for systematic reviews of interventions adherence to treatment of postmenopausal osteoporosis
[EB/OL]. [2024-04-20]. https：//training.cochrane.org/ with raloxifene and/or alfacalcidol in postmenopausal
handbook. Japanese women[J]. J Bone Miner Metab，2010，28（2）：
[14] BOW C H，CHEUNG E，CHEUNG C L，et al. Ethnic dif‐ 176-184.
ference of clinical vertebral fracture risk[J]. Osteoporos [28] KONDO S，KAKIHATA H，NISHIDA Y，et al. The safety
Int，2012，23（3）：879-885. and effectiveness profile of eldecalcitol in a prospective，
[15] LOFTHUS C M，FRIHAGEN F，MEYER H E，et al. Epi‐ post-marketing observational study in Japanese male pa‐
demiology of distal forearm fractures in Oslo，Norway[J]. tients with osteoporosis[J]. J Bone Miner Metab，2019，37
Osteoporos Int，2008，19（6）：781-786. （2）：292-300.
[16] MORI T，CRANDALL C J，GANZ D A. Cost- [29] MOCHIZUKI T，YANO K，IKARI K，et al. Two-year ef‐
effectiveness of combined oral bisphosphonate therapy fectiveness of zoledronic acid with or without eldecalcitol
and falls prevention exercise for fracture prevention in the in Japanese patients with osteoporosis：a randomized pro‐
USA[J]. Osteoporos Int，2017，28（2）：585-595. spective study[J]. Osteoporos Sarcopenia，2022，8（2）：
[17] SI L，WINZENBERG T M，JIANG Q，et al. Screening for 75-79.
and treatment of osteoporosis：construction and validation [30] SUZUKI T，NAKAMURA Y，KATO H. Efficacy，safety，

· 1214 · China Pharmacy 2025 Vol. 36 No. 10 中国药房 2025年第36卷第10期